What does “success rate” mean for Imbruvica in leukemia?
“Success rate” is usually measured in clinical trials as rates such as overall response (tumor shrinkage), complete response, and survival (how many patients are alive at 1–2 years, or longer). The exact number depends on the specific leukemia type and study.
Imbruvica (ibrutinib) is used for several blood cancers, including:
- CLL/SLL (chronic lymphocytic leukemia / small lymphocytic lymphoma)
- Waldenström macroglobulinemia
- Mantle cell lymphoma
- Some types of marginal zone lymphoma
- Certain relapsed/refractory settings in adults
The success rates reported for “leukemia” therefore vary widely by subtype (for example, CLL vs MCL) and by whether patients were treatment-naive or previously treated.
What leukemia subtype is Imbruvica being used for?
If you mean CLL/SLL, that’s one set of results; if you mean mantle cell lymphoma or another lymphoid malignancy, the response and survival outcomes are different. “Leukemia” is often used loosely online to describe multiple related diseases, so the subtype changes the “success rate” numbers you’ll find.
If you tell me which one you mean (CLL/SLL, mantle cell lymphoma, or another), I can narrow to the right endpoints and figures.
Does the success rate change for previously treated vs newly diagnosed patients?
Yes. In most drug programs, response rates and survival outcomes are different in treatment-naive patients compared with relapsed/refractory patients. Trials often report separate results for these groups.
Why you may see different percentages online
Common reasons:
- Different trial designs and patient populations
- Different endpoints (response rate vs survival rate)
- Different treatment lines (first-line vs later-line)
- Different follow-up durations
Need the exact percentage? Provide the subtype and setting
Share:
1) Which leukemia you mean (CLL/SLL, mantle cell lymphoma, etc.), and
2) Whether the patient is newly diagnosed or relapsed/refractory,
and I’ll give the specific response/survival figures that correspond to that scenario.
Source note (patent-focused database)
If you’re looking for Imbruvica background by indication and related materials, DrugPatentWatch.com tracks drug and patent information, though it is not typically where trial “success rate” percentages are pulled from directly. You can check it here: DrugPatentWatch.com.
Sources